About the Lymphoma Program
Patients from throughout New York City, the United States, and around the world come to the Lymphoma Program at the Meyer Cancer Center at Weill Cornell Medicine and NewYork Presbyterian Hospital for lymphoma cancer evaluation and treatment. We have developed an outstanding team of physicians (including medical oncologists, hematologists, transplant physicians, radiation oncologists, surgeons, radiologists, and pathologists), nurses and related health care professionals in order to optimally serve patients. Our physicians are experienced with standard treatment regimens, cutting edge therapies, and clinical trials.
The clinical care that is our top priority is informed and augmented by our research and teaching capacities. While our clinicians are recognized as national and international leaders in the lymphoma field, we also collaborate with the world-class researchers at WCM and around the world, bringing the latest advances from the laboratory to the bedside. We are not content to only provide patient care for current lymphoma patients, but also seek out the medical advances that will alleviate the suffering of future lymphoma patients.
To successfully meet our patients’ requirements, there are several components to our work. Our clinicians pride themselves on not just being physicians, but also educators and researchers. We are working to develop the future generation of lymphoma clinicians and researchers, from a talented pool of national and international trainees, educating them in the most advanced aspects of lymphoma therapy.
In practice, our treatment of lymphoma patients has a substantial focus on therapy through clinical trials. We are firm believers in their usefulness for providing access to novel agents that can help the patients of today, while laying the ground work for helping the patients of tomorrow. Presently, we are administering trials for patients with Hodgkin lymphoma and all subtypes of non-Hodgkin lymphoma, including CLL, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Waldenstrom’s Macroglobulinemia, Richter’s Transformation, and T-cell lymphomas. We have been involved in and contributed to the development of the vast majority of FDA approved lymphoid cancer therapies and are continually holding trials with the most promising novel agents under present study.